24/7 Market News Snapshot 12 February, 2025 – INmune Bio Inc. Common stock (NASDAQ:INMB)

February 12, 2025

DENVER, Colo., 12 February, 2025 (247marketnews.com) – (NASDAQ:INMB) are discussed in this article.
INmune Bio Inc. (INMB) has experienced a notable surge in stock value, with shares opening at $8.50 and reaching a height of $8.985, reflecting an impressive increase of about 8.91%. This escalation follows last session’s closing price of $8.25 and suggests a considerable level of investor engagement, as indicated by the current trading volume of 830.20K. Such robust activity may result in heightened volatility, making it important for investors to monitor the stock’s resistance levels around $9.00 and analyze volume trends to accurately assess its momentum and potential for further appreciation.

In addition to its market performance, INmune Bio is making significant strides in clinical research, particularly with its innovative Natural Killer (NK) cell therapy, INKmune™. The Company has successfully completed the third and highest dose cohort in its ongoing Phase I/II trial, named the “CaRe PC” trial, which targets men with metastatic castration-resistant prostate cancer (mCRPC). The Scientific Review Committee (SRC) has unanimously approved the opening of all Phase II cohorts for patient enrollment, allowing for a deeper investigation of INKmune™ efficacy at elevated dosage levels.

Dr. RJ Tesi, CEO of INmune Bio, stated that the excellent safety profile observed thus far allows for outpatient administration, enhancing patient accessibility to this therapy. Preliminary data from earlier cohorts have shown encouraging immunologic responses, which are critical as the trial advances. Mark Lowdell, Chief Scientific Officer and inventor of INKmune™, is anticipated to share pivotal findings at the upcoming 10th Annual Innate Killer Summit in early March, highlighting the innovative application of INKmune™ in managing mCRPC.

As INmune Bio continues to focus on chronic inflammation and cancer treatment, it reinforces its dedication to leveraging the innate immune system in advancing therapeutics aimed at combating complex diseases. This comprehensive approach positions INmune Bio at the forefront of immunotherapy development, with promising prospects for future breakthroughs.

Related news for (INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.